Coronary disease & ACSMeta-analysis

Baseline anaemia and short dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention

Eur J Prev CardiolPublished

  • Pooled analysis of three prospective trials (XIENCE Short dual antiplatelet therapy (DAPT) Program)
  • propensity score stratification
  • subgroup analysis by baseline anaemia

Authors' conclusion

Among HBR patients undergoing PCI, abbreviated DAPT was associated with comparable ischemic outcomes regardless of anemia status. In patients with baseline anemia, 1-month DAPT was associated with lower major bleeding without an apparent ischemic trade-off.

Study context

Population
High bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI) with cobalt-chromium everolimus-eluting stents; anaemia = Hb <11 g/dL514 (15.3%) anaemic
Participants
3,364 patients
Comparison
1-month vs 3-month DAPT by baseline anaemia
Outcome
All-cause death or MI
Follow-up
1 year

Pooled result

As reported in the abstract

All-cause death or MI, anaemic patients (subgroup)

Adjusted hazard ratio

0.94

95% CI 0.59–1.52

P = 0.807

By group

1-month DAPT vs 3-month DAPT
adjusted HR 0.94 (95% CI 0.59–1.52); P = 0.807

Further pooled results

Ischaemic and bleeding events, anaemic vs non-anaemic · 1 year

Anaemic patients had higher rates of both ischaemic and bleeding events than non-anaemic patients

Safety

Outcome1-month DAPT3-month DAPTadjusted HR (95% CI)P value
Major bleeding, anaemic patients (subgroup) · 1 year6.1%11.1%0.49 (0.24–1.00)P = 0.050

Major bleeding, anaemic patients (subgroup) · 1 year

Non-anaemic patients: bleeding outcomes similar irrespective of DAPT duration

Original publication

Baseline anaemia and short dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention. Eur J Prev Cardiol. Published 23 July 2026. doi:10.1093/eurjpc/zwag384

Summarised from the published abstract; every number is checked against it